Outcomes
Cancer, death, tumor, fever, abdominal pain, SD, PD, decreased appetite, nausea, vomiting
TUMOR, ADVERSE EVENTS, ADVERSE EVENT, DISEASE, SOLID TUMOR, TUMOR PROGRESSION, SYNDROME, ISCHEMIC NECROSIS, CANCER
Efficacy outcomes included complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Efficacy was assessed according to Modified solid tumor Evaluation Criteria (mRECIST) and RECIST version 1.1. DCR was defined as the sum of CR, PR, and SD. PFS referred to the time between the initiation of combination therapy and tumor progression or death from any cause. OS referred to the time from the start of combination therapy to the last follow-up or the time of death from any cause.Adverse events (AEs) were evaluated using the National Cancer Institute Common Terminology Criteria for adverse events version 5.0. Post-embolization syndrome after TACE treatment referred to a series of clinical symptoms such as nausea, vomiting, abdominal pain, fever, and decreased appetite caused by ischemic necrosis of tumor tissue after TACE treatment.